Company Profile

Attagene Inc
Profile last edited on: 12/3/19      CAGE: 4P3V1      UEI: Z8AYGD59N8U4

Business Identifier: Screening services for the evaluation of biological activities & prediction of potential toxicities
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

7020 Kit Creek Road Suite 260
Morrisville, NC 27560
   (919) 313-0167
Location: Single
Congr. District: 04
County: Wake

Public Profile

Attagene, Inc. is structured around accelerating drug discovery and development by providing innovative tools for examining signal transduction. Research scientists on the team have both academic and industrial backgrounds that combine expertise in signal transduction, functional genomics and gene discovery with knowledge of disease pathology. Developing transforming technologies for drug development and toxicity testing, the company has invented and commercialized the first multiplexed reporter technology (the FACTORIAL(TM)) for quantitative assessment of multiple signal transduction pathways in living cells. Using this platform, principals of the firm have developed new straightforward approaches to drug discovery and development and to the assessment of mechanisms underlying the toxicity of environmental chemicals. The firm offers unique screening services for the evaluation of biological activities and prediction of potential toxicities of pharmaceuticals, agricultural and industrial chemicals, cosmetics, and nanomaterials. Using its proprietary pathway-profiling platform - the FACTORIAL - Attagene has developed a suite of bioassays that assess the impact of a compound on activities of over ninety gene regulatory pathways and all forty-eight human nuclear receptors. FACTORIAL assays proved their utility for the evaluation of bioactivities of very different compounds, including chemicals, biologicals, nanomaterials and complex mixtures. FACTORIAL assays are available in many cell types and systems, from human and animal cell lines to primary cells to entire organs of live animals enabling the firm to establish an important position in development of pathway profiling technologies for drug development, toxicology and biomedicine. To accommodate changing environment, cell alters gene expression program. This adaptive response is mediated by intracellular network of regulatory pathways that relay to genomic DNA the signals that modulate gene expression. The signaling pathways communicate with DNA by using transcription factors (TFs), proteins that bind specific sequences within target genes. By assessing TFs’ activities one can characterize the functional status of cellular gene regulatory networ

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 2 NIH $1,999,996
Project Title: Assessing the Polypharmacology of Kinase Inhibitors by Transcription Factor Activity Profiling
2019 2 NIH $2,990,161
Project Title: Predicting DILI liability by transcription factor profiling
2004 2 NIH $292,384
Project Title: Profiling of signal transduction pathways in cancer
2004 2 NIH $641,523
Project Title: Novel biosensors for toxicological applications
0 1 NIH $1,000,000
Project Title: Assigning mode of action to phenotypically discovered anticancer leads.

Key People / Management

  Sergei S Makarov -- President; Chief Executive Officer

  Alex Medvedev -- Research Director

Company News

There are no news available.